Full Interview: Algernon Pharmaceuticals Receives OK From South Korea for Phase Two Study of Ifenprodil (Proactive)

Full Interview: Algernon Pharmaceuticals Receives OK From South Korea for Phase Two Study of Ifenprodil

Christopher Moreau, CEO of UF startup Algernon Pharmaceuticals, a clinical-stage pharmaceutical development company, joined Steve Darling from Proactive in Vancouver with big news. The company has received approval from the Ministry of Food and Drug Safety in South Korea for a Phase 2 COVID-19 clinical study of their repurposed drug Ifenprodil . 

Moreau shares with Proactive how this study will be conducted and where they are as far as Health Canada is concerned.

Learn more about Full Interview: Algernon Pharmaceuticals Receives OK From South Korea for Phase Two Study of Ifenprodil.
Related news Full Interview: Algernon Pharmaceuticals Announces Regulatory Submission for COVID-19 Trial in South Korea.
X